Endless schreef op 11 maart 2025 08:08:
Pharming Group NV is expected to show a fall in quarterly revenue when it reports results on March 13 for the period ending December 31 2024
The Leiden Zuid-holland-based company is expected to report a 0.6% decrease in revenue to $80.743 million from $81.22 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
?LSEG's mean analyst estimate for Pharming Group NV is for earnings of 1 cent per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months. ?
[b]Wall Street's median 12-month price target for Pharming Group NV is €2.10?, above? its last closing price of €0.74. ???[/b]
Previous quarterly performance (using preferred earnings measure in US dollars). ?
Verwachting analisten
[